S. Lasserre

477 total citations
9 papers, 323 citations indexed

About

S. Lasserre is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, S. Lasserre has authored 9 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Genetics. Recurrent topics in S. Lasserre's work include Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). S. Lasserre is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). S. Lasserre collaborates with scholars based in Switzerland, France and Spain. S. Lasserre's co-authors include Ian Chau, Pilar Alfonso, John Bridgewater, Michel Rivoire, Daniel Waterkamp, René Adam, Thomas Gruenberger, Matthias Hermann, Satvinder Mudan and Giovanni Martinelli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

S. Lasserre

9 papers receiving 318 citations

Peers

S. Lasserre
Nicolas Sommer United States
A. Astone Italy
Nicolas Moosmann Germany
Jean-Claude Vedovato France
Jayne Gurtler United States
Mengxuan Zuo China
Jang-Chun Lin Taiwan
Mark Karwal United States
N. E. Kemeny United States
Javier Sastre Valera Spain
Nicolas Sommer United States
S. Lasserre
Citations per year, relative to S. Lasserre S. Lasserre (= 1×) peers Nicolas Sommer

Countries citing papers authored by S. Lasserre

Since Specialization
Citations

This map shows the geographic impact of S. Lasserre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Lasserre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Lasserre more than expected).

Fields of papers citing papers by S. Lasserre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Lasserre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Lasserre. The network helps show where S. Lasserre may publish in the future.

Co-authorship network of co-authors of S. Lasserre

This figure shows the co-authorship network connecting the top 25 collaborators of S. Lasserre. A scholar is included among the top collaborators of S. Lasserre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Lasserre. S. Lasserre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
2.
Raje, Noopur, Ian Chau, David M. Hyman, et al.. (2015). Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. Blood. 126(23). 4263–4263. 9 indexed citations
3.
Gruenberger, Thomas, John Bridgewater, Ian Chau, et al.. (2014). Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Annals of Oncology. 26(4). 702–708. 225 indexed citations
4.
5.
Adam, René, John Bridgewater, Ian Chau, et al.. (2013). Randomised, Phase 2 Study (OLIVIA) of Bevacizumab Plus mFOLFOX6 or Folfoxiri in Patients with Initially Unresectable Colorectal Cancer Liver Metastases. Annals of Oncology. 24. iv21–iv21. 3 indexed citations
6.
Gruenberger, Thomas, John Bridgewater, Ian Chau, et al.. (2013). Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA.. Journal of Clinical Oncology. 31(15_suppl). 3619–3619. 18 indexed citations
7.
8.
Rohr, Ulrich‐Peter, et al.. (2009). Safety of bevacizumab in patients with metastases to the central nervous system. Journal of Clinical Oncology. 27(15_suppl). 2007–2007. 8 indexed citations
9.
Lasserre, S., et al.. (2008). Un torticolis fébrile : présentation atypique d’une maladie de Kawasaki. Archives de Pédiatrie. 16(2). 115–117. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolas Sommer Breakdown of academic impact, for papers by A. Astone Breakdown of academic impact, for papers by Nicolas Moosmann Breakdown of academic impact, for papers by Jean-Claude Vedovato Breakdown of academic impact, for papers by Jayne Gurtler Breakdown of academic impact, for papers by Mengxuan Zuo Breakdown of academic impact, for papers by Jang-Chun Lin Breakdown of academic impact, for papers by Mark Karwal Breakdown of academic impact, for papers by N. E. Kemeny Breakdown of academic impact, for papers by Javier Sastre Valera
Rankless by CCL
2026